THERAPY DOSSIER · th-4219daa3a19a

agomiR-21 and agomiR-146a (cholesterol-conjugated microRNA mimics)

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26978580 ↗2016Reported benefit

Combination of microRNA-21 and microRNA-146a Attenuates Cardiac Dysfunction and Apoptosis During Acute Myocardial Infarction in Mice.

MouseIschaemia-reperfusionCardiacKunmingMaleIntramuscular injection into the left ventricular myocardium at multiple sitesagomiR-21 100 nmol/kg, agomiR-146a 100 nmol/kg, combination…24 h before coronary artery ligation

Model: Acute myocardial infarction by left anterior descending coronary artery ligation

Combined agomiR-21 and agomiR-146a reduced infarct size and cardiomyocyte apoptosis and improved ejection fraction and fractional shortening more than either microRNA alone. Infarction raised caspase-3 mRNA about 5.5-fold, caspase-3 activity about 3.0-fold and p-p38 MAPK 2.3-fold, all attenuated mo…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.88. Machine-extracted fields require source verification.

Loading the evidence…